Eric Christenson
Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Medical Institution · Johns Hopkins Sidney Kimmel Comprehensive Cancer Center · SKCCC • Johns Hopkins Medical Institution
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Eric Christenson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:55 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07580339 · Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · not yet recruiting · Rectal Cancer · principal investigator
- Ph2NCT07281768 · Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · recruiting · Colorectal Cancer · principal investigator
- Ph1/Ph2NCT06782932 · Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · recruiting · Pancreatic Cancer · principal investigator
- Ph2NCT06205836 · Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · recruiting · Colorectal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical TrialR01CA197296 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2026 · $580,237 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:55 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- Restricting night-time eating reduces daily energy intake in healthy young men: a short-term cross-over study.Br J Nutr · 201387 citationsRCR 2.9
- Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.Clin Cancer Res · 202515 citationsRCR 2.6
- Is aprotinin safe to use in a cohort at increased risk for thrombotic events: results from a randomized, prospective trial in off-pump coronary artery bypass.Ann Thorac Surg · 20087 citationsRCR 0.2